Follow
Stephane de Botton
Stephane de Botton
MCU-PH _ Gustave Roussy
Verified email at igr.fr
Title
Cited by
Cited by
Year
Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia
EM Stein, CD DiNardo, DA Pollyea, AT Fathi, GJ Roboz, JK Altman, ...
Blood, The Journal of the American Society of Hematology 130 (6), 722-731, 2017
14422017
Durable Remissions with Ivosidenib in IDH1-Mutated Relapsed or Refractory AML
CD DiNardo, EM Stein, S de Botton, GJ Roboz, JK Altman, AS Mims, ...
New England Journal of Medicine 378 (25), 2386-2398, 2018
13382018
Targeted inhibition of mutant IDH2 in leukemia cells induces cellular differentiation
F Wang, J Travins, B DeLaBarre, V Penard-Lacronique, S Schalm, ...
Science 340 (6132), 622-626, 2013
9312013
Favorable prognostic significance of CEBPA mutations in patients with de novo acute myeloid leukemia: a study from the Acute Leukemia French Association (ALFA)
C Preudhomme, C Sagot, N Boissel, JM Cayuela, I Tigaud, S de Botton, ...
Blood, The Journal of the American Society of Hematology 100 (8), 2717-2723, 2002
6182002
Prognostic factors for response and overall survival in 282 patients with higher-risk myelodysplastic syndromes treated with azacitidine
R Itzykson, S Thépot, B Quesnel, F Dreyfus, O Beyne-Rauzy, P Turlure, ...
Blood, The Journal of the American Society of Hematology 117 (2), 403-411, 2011
4532011
Incidence and prognostic impact of c-Kit, FLT3, and Ras gene mutations in core binding factor acute myeloid leukemia (CBF-AML)
N Boissel, H Leroy, B Brethon, N Philippe, S De Botton, A Auvrignon, ...
Leukemia 20 (6), 965-970, 2006
4532006
Incidence, Clinical Features, and Outcome of AllTrans-Retinoic Acid Syndrome in 413 Cases of Newly Diagnosed Acute Promyelocytic Leukemia
S De Botton, H Dombret, M Sanz, JS Miguel, D Caillot, R Zittoun, ...
Blood, The Journal of the American Society of Hematology 92 (8), 2712-2718, 1998
4291998
Platelet formation is the consequence of caspase activation within megakaryocytes
S De Botton, S Sabri, E Daugas, Y Zermati, JE Guidotti, O Hermine, ...
Blood, The Journal of the American Society of Hematology 100 (4), 1310-1317, 2002
4262002
AG-221, a First-in-Class Therapy Targeting Acute Myeloid Leukemia Harboring Oncogenic IDH2 Mutations
K Yen, J Travins, F Wang, MD David, E Artin, K Straley, A Padyana, ...
Cancer discovery 7 (5), 478-493, 2017
4102017
Discovery of AG-120 (Ivosidenib): a first-in-class mutant IDH1 inhibitor for the treatment of IDH1 mutant cancers
J Popovici-Muller, RM Lemieux, E Artin, JO Saunders, FG Salituro, ...
ACS medicinal chemistry letters 9 (4), 300-305, 2018
3722018
Enasidenib induces acute myeloid leukemia cell differentiation to promote clinical response
MD Amatangelo, L Quek, A Shih, EM Stein, M Roshal, MD David, ...
Blood, The Journal of the American Society of Hematology 130 (6), 732-741, 2017
3682017
Molecular remission and response patterns in patients with mutant-IDH2 acute myeloid leukemia treated with enasidenib
EM Stein, CD DiNardo, AT Fathi, DA Pollyea, RM Stone, JK Altman, ...
Blood, The Journal of the American Society of Hematology 133 (7), 676-687, 2019
3502019
Very long-term outcome of acute promyelocytic leukemia after treatment with all-trans retinoic acid and chemotherapy: the European APL Group experience
L Ades, A Guerci, E Raffoux, M Sanz, P Chevallier, S Lapusan, C Recher, ...
Blood, The Journal of the American Society of Hematology 115 (9), 1690-1696, 2010
3472010
Ivosidenib induces deep durable remissions in patients with newly diagnosed IDH1-mutant acute myeloid leukemia
GJ Roboz, CD DiNardo, EM Stein, S de Botton, AS Mims, GT Prince, ...
Blood, The Journal of the American Society of Hematology 135 (7), 463-471, 2020
3152020
High efficacy and safety profile of fractionated doses of Mylotarg as induction therapy in patients with relapsed acute myeloblastic leukemia: a prospective study of the alfa group
AL Taksin, O Legrand, E Raffoux, T De Revel, X Thomas, N Contentin, ...
Leukemia 21 (1), 66-71, 2007
3112007
Prevalence, clinical profile, and prognosis of NPM mutations in AML with normal karyotype
N Boissel, A Renneville, V Biggio, N Philippe, X Thomas, JM Cayuela, ...
Blood 106 (10), 3618-3620, 2005
2942005
Mutations affecting mRNA splicing define distinct clinical phenotypes and correlate with patient outcome in myelodysplastic syndromes
F Damm, O Kosmider, V Gelsi-Boyer, A Renneville, N Carbuccia, ...
Blood, The Journal of the American Society of Hematology 119 (14), 3211-3218, 2012
2902012
TET2 gene mutation is a frequent and adverse event in chronic myelomonocytic leukemia
O Kosmider, V Gelsi-Boyer, M Ciudad, C Racoeur, V Jooste, N Vey, ...
Haematologica 94 (12), 1676, 2009
2822009
Postinduction Minimal Residual Disease Predicts Outcome and Benefit From Allogeneic Stem Cell Transplantation in Acute Myeloid Leukemia With NPM1 Mutation …
M Balsat, A Renneville, X Thomas, S De Botton, D Caillot, A Marceau, ...
Journal of Clinical Oncology 35 (2), 185-193, 2017
2742017
Ecto‐calreticulin in immunogenic chemotherapy
M Obeid, A Tesniere, T Panaretakis, R Tufi, N Joza, P Van Endert, ...
Immunological reviews 220 (1), 22-34, 2007
2522007
The system can't perform the operation now. Try again later.
Articles 1–20